-
1
-
-
0029838815
-
Systematic search for variation in the human norepinephrine transporter gene: Identification of five naturally occurring missense mutations and study of association with major psychiatric disorders
-
Stöber G, Nöthen MM, Pörzgen P, et al. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet. 1996;67:523-532.
-
(1996)
Am J Med Genet
, vol.67
, pp. 523-532
-
-
Stöber, G.1
Nöthen, M.M.2
Pörzgen, P.3
-
2
-
-
33645316100
-
The norepinephrine transporter and its regulation
-
Mandela P, Ordway GA. The norepinephrine transporter and its regulation. J Neurochem. 2006;97:310-333.
-
(2006)
J Neurochem
, vol.97
, pp. 310-333
-
-
Mandela, P.1
Ordway, G.A.2
-
3
-
-
0037144350
-
Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells
-
Höpfner M, Sutter AP, Beck NI, et al. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Int J Cancer. 2002;101:210-216.
-
(2002)
Int J Cancer
, vol.101
, pp. 210-216
-
-
Höpfner, M.1
Sutter, A.P.2
Beck, N.I.3
-
5
-
-
0026067920
-
Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C)
-
Lashford LS, Hancock JP, Kemshead JT. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer. 1991;47:105-109.
-
(1991)
Int J Cancer
, vol.47
, pp. 105-109
-
-
Lashford, L.S.1
Hancock, J.P.2
Kemshead, J.T.3
-
6
-
-
18544405718
-
Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
-
Kölby L, Bernhardt P, Levin-Jakobsen AM, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer. 2003;89:1383-1388.
-
(2003)
Br J Cancer
, vol.89
, pp. 1383-1388
-
-
Kölby, L.1
Bernhardt, P.2
Levin-Jakobsen, A.M.3
-
7
-
-
0023218242
-
Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison
-
Bomanji J, Levison DA, Flatman WD, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987;28:973-978.
-
(1987)
J Nucl Med
, vol.28
, pp. 973-978
-
-
Bomanji, J.1
Levison, D.A.2
Flatman, W.D.3
-
8
-
-
84876543336
-
Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: A report from the Children's Oncology Group
-
Dubois SG, Geier E, Batra V, et al. Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: a report from the Children's Oncology Group. Int J Mol Imaging. 2012;2012:250834.
-
(2012)
Int J Mol Imaging
, vol.2012
, pp. 250834
-
-
Dubois, S.G.1
Geier, E.2
Batra, V.3
-
9
-
-
0025726824
-
Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging
-
Gaze MN, Huxham IM, Mairs RJ, Barrett A. Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer. 1991;47:875-880.
-
(1991)
Int J Cancer
, vol.47
, pp. 875-880
-
-
Gaze, M.N.1
Huxham, I.M.2
Mairs, R.J.3
Barrett, A.4
-
10
-
-
33750454805
-
Exploiting the MIBG-avidity of neuroblastoma for staging and treatment
-
Kushner BH, Cheung NK. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer. 2006;47:863-864.
-
(2006)
Pediatr Blood Cancer
, vol.47
, pp. 863-864
-
-
Kushner, B.H.1
Cheung, N.K.2
-
11
-
-
80053070127
-
Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project
-
Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243-257.
-
(2011)
Radiology
, vol.261
, pp. 243-257
-
-
Brisse, H.J.1
McCarville, M.B.2
Granata, C.3
-
12
-
-
77951688395
-
Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force
-
Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319-1326.
-
(2010)
Br J Cancer
, vol.102
, pp. 1319-1326
-
-
Matthay, K.K.1
Shulkin, B.2
Ladenstein, R.3
-
13
-
-
58249093954
-
The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report
-
Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298-303.
-
(2009)
J Clin Oncol
, vol.27
, pp. 298-303
-
-
Monclair, T.1
Brodeur, G.M.2
Ambros, P.F.3
-
14
-
-
60549083512
-
MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma
-
Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008; 52:388-402.
-
(2008)
Q J Nucl Med Mol Imaging
, vol.52
, pp. 388-402
-
-
Boubaker, A.1
Bischof Delaloye, A.2
-
15
-
-
0029743648
-
Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging
-
Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med. 1996;37:1464-1468.
-
(1996)
J Nucl Med
, vol.37
, pp. 1464-1468
-
-
Rufini, V.1
Fisher, G.A.2
Shulkin, B.L.3
Sisson, J.C.4
Shapiro, B.5
-
16
-
-
77954522656
-
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis
-
Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010;95:2596-2606.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 2596-2606
-
-
Jacobson, A.F.1
Deng, H.2
Lombard, J.3
Lessig, H.J.4
Black, R.R.5
-
17
-
-
67650481556
-
123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial
-
Vik TA, Pfluger T, Kadota R, et al. 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784-790.
-
(2009)
Pediatr Blood Cancer
, vol.52
, pp. 784-790
-
-
Vik, T.A.1
Pfluger, T.2
Kadota, R.3
-
18
-
-
61449184564
-
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
-
Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041-1046.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1041-1046
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
Cheung, N.K.4
-
19
-
-
0028127893
-
What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?
-
Labreveux de Cervens C, Hartmann O, Bonnin F, et al. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age? Med Pediatr Oncol. 1994;22:107-114.
-
(1994)
Med Pediatr Oncol
, vol.22
, pp. 107-114
-
-
Labreveux De Cervens, C.1
Hartmann, O.2
Bonnin, F.3
-
20
-
-
46049096104
-
The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma .1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97
-
Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma .1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552-1558.
-
(2008)
Eur J Cancer
, vol.44
, pp. 1552-1558
-
-
Schmidt, M.1
Simon, T.2
Hero, B.3
Schicha, H.4
Berthold, F.5
-
21
-
-
0038013985
-
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
-
Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21: 2486-2491.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2486-2491
-
-
Matthay, K.K.1
Edeline, V.2
Lumbroso, J.3
-
22
-
-
5444224345
-
Scintigraphic response by 123Imetaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma
-
Katzenstein HM, Cohn SL, Shore RM, et al. Scintigraphic response by 123Imetaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909-3915.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3909-3915
-
-
Katzenstein, H.M.1
Cohn, S.L.2
Shore, R.M.3
-
23
-
-
79954603164
-
18F-FDG PET/CT and 123Imetaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis
-
Papathanasiou ND, Gaze MN, Sullivan K, et al. 18F-FDG PET/CT and 123Imetaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med. 2011;52:519-525.
-
(2011)
J Nucl Med
, vol.52
, pp. 519-525
-
-
Papathanasiou, N.D.1
Gaze, M.N.2
Sullivan, K.3
-
24
-
-
0025570887
-
Radioiodinated metaiodobenzylguanidine (I-MIBG) scintigraphy in neuroblastoma: A review of 160 studies
-
Troncone L, Rufini V, Danza FM, et al. Radioiodinated metaiodobenzylguanidine (I-MIBG) scintigraphy in neuroblastoma: a review of 160 studies. J Nucl Med Allied Sci. 1990;34:279-288.
-
(1990)
J Nucl Med Allied Sci
, vol.34
, pp. 279-288
-
-
Troncone, L.1
Rufini, V.2
Danza, F.M.3
-
25
-
-
0023607958
-
Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986
-
Feine U, Müller-Schauenburg W, Treuner J, Klingebiel T. Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol. 1987;15:181-187.
-
(1987)
Med Pediatr Oncol
, vol.15
, pp. 181-187
-
-
Feine, U.1
Müller-Schauenburg, W.2
Treuner, J.3
Klingebiel, T.4
-
26
-
-
0037445249
-
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
-
Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082-1086.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1082-1086
-
-
Kushner, B.H.1
Yeh, S.D.2
Kramer, K.3
Larson, S.M.4
Cheung, N.K.5
-
27
-
-
0029421760
-
[123i]MIBG scintigraphy in neuroblastoma: A comparison between planar and SPECT imaging
-
Rufini V, Giordano A, Di Giuda D, et al. [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med. 1995;39(suppl 1):25-28.
-
(1995)
Q J Nucl Med
, vol.39
, pp. 25-28
-
-
Rufini, V.1
Giordano, A.2
Di Giuda, D.3
-
28
-
-
78651098648
-
Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma
-
Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 2011; 36:1-7.
-
(2011)
Clin Nucl Med
, vol.36
, pp. 1-7
-
-
Fukuoka, M.1
Taki, J.2
Mochizuki, T.3
Kinuya, S.4
-
29
-
-
84982903057
-
Superiority of SPECT/CT over planar 123ImIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values
-
Černý I, Prášek J, Kašpárková H. Superiority of SPECT/CT over planar 123ImIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 2016;55;151-157.
-
(2016)
Nuklearmedizin
, vol.55
, pp. 151-157
-
-
Černý, I.1
Prášek, J.2
Kašpárková, H.3
-
30
-
-
0028926663
-
A new 123I-MIBG whole body scan scoring method: Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma
-
Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method: application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995; 31A:256-261.
-
(1995)
Eur J Cancer
, vol.31 A
, pp. 256-261
-
-
Ady, N.1
Zucker, J.M.2
Asselain, B.3
-
31
-
-
33750483287
-
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
-
Messina JA, Cheng SC, Franc B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47:865-874.
-
(2006)
Pediatr Blood Cancer
, vol.47
, pp. 865-874
-
-
Messina, J.A.1
Cheng, S.C.2
Franc, B.3
-
32
-
-
84969611117
-
Evaluation of the SIOPEN semiquantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma
-
Radovic B, Artiko V, Sobic-Saranovic D, et al. Evaluation of the SIOPEN semiquantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma. Neoplasma. 2015;62:449-455.
-
(2015)
Neoplasma
, vol.62
, pp. 449-455
-
-
Radovic, B.1
Artiko, V.2
Sobic-Saranovic, D.3
-
33
-
-
84988715304
-
123I-mIBG scintigraphy in neuroblastoma: Development of a SIOPEN semi-quantitative reporting method by an international panel
-
Lewington V, Lambert B, Poetschger U, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44:234-241.
-
(2017)
Eur J Nucl Med Mol Imaging
, vol.44
, pp. 234-241
-
-
Lewington, V.1
Lambert, B.2
Poetschger, U.3
-
34
-
-
84875768440
-
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group
-
Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. J Nucl Med. 2013;54:541-548.
-
(2013)
J Nucl Med
, vol.54
, pp. 541-548
-
-
Yanik, G.A.1
Parisi, M.T.2
Shulkin, B.L.3
-
35
-
-
73949148794
-
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma
-
Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343-5349.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5343-5349
-
-
Taggart, D.R.1
Han, M.M.2
Quach, A.3
-
36
-
-
61449217017
-
Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A New Approaches to Neuroblastoma Therapy phase i study
-
Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a New Approaches to Neuroblastoma Therapy phase I study. J Clin Oncol. 2009;27: 1020-1025.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1020-1025
-
-
Matthay, K.K.1
Quach, A.2
Huberty, J.3
-
37
-
-
0023206022
-
Pheochromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy
-
Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology. 1987;165:89-93.
-
(1987)
Radiology
, vol.165
, pp. 89-93
-
-
Quint, L.E.1
Glazer, G.M.2
Francis, I.R.3
Shapiro, B.4
Chenevert, T.L.5
-
38
-
-
0035156972
-
The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines
-
Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001;91: 35-62.
-
(2001)
Pharmacol Ther
, vol.91
, pp. 35-62
-
-
Eisenhofer, G.1
-
39
-
-
0037896855
-
[123I] metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas
-
van der Harst E, de Herder WW, Bruining HA, et al. [123I]metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685-693.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 685-693
-
-
Van Der Harst, E.1
De Herder, W.W.2
Bruining, H.A.3
-
40
-
-
47549111966
-
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation
-
Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69: 181-188.
-
(2008)
Clin Endocrinol (Oxf)
, vol.69
, pp. 181-188
-
-
Bhatia, K.S.1
Ismail, M.M.2
Sahdev, A.3
-
41
-
-
34247619702
-
The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome
-
Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156: 483-487.
-
(2007)
Eur J Endocrinol
, vol.156
, pp. 483-487
-
-
Kaji, P.1
Carrasquillo, J.A.2
Linehan, W.M.3
-
42
-
-
69449086667
-
Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial
-
Wiseman GA, Pacak K, O'Dorisio M, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50:1448-1454.
-
(2009)
J Nucl Med
, vol.50
, pp. 1448-1454
-
-
Wiseman, G.A.1
Pacak, K.2
O'Dorisio, M.3
-
43
-
-
33745068054
-
A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma
-
Cecchin D, Lumachi F, Marzola MC, et al. A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer. 2006;13:525-533.
-
(2006)
Endocr Relat Cancer
, vol.13
, pp. 525-533
-
-
Cecchin, D.1
Lumachi, F.2
Marzola, M.C.3
-
44
-
-
0021280819
-
Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine [letter]
-
Fischer M, Kamanabroo D, Sonderkamp H, Proske T. Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine [letter]. Lancet. 1984;2:165.
-
(1984)
Lancet
, vol.2
, pp. 165
-
-
Fischer, M.1
Kamanabroo, D.2
Sonderkamp, H.3
Proske, T.4
-
45
-
-
0023009538
-
Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors
-
Feldman JM, Blinder RA, Lucas KJ, Coleman RE. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med. 1986;27:1691-1696.
-
(1986)
J Nucl Med
, vol.27
, pp. 1691-1696
-
-
Feldman, J.M.1
Blinder, R.A.2
Lucas, K.J.3
Coleman, R.E.4
-
46
-
-
0024346147
-
Carcinoid tumors: Iodine-131 MIBG scintigraphy
-
Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology. 1989;172:699-703.
-
(1989)
Radiology
, vol.172
, pp. 699-703
-
-
Hanson, M.W.1
Feldman, J.M.2
Blinder, R.A.3
Moore, J.O.4
Coleman, R.E.5
-
47
-
-
77957094063
-
PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine
-
Watanabe S, Hanaoka H, Liang JX, Iida Y, Endo K, Ishioka NS. PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine. J Nucl Med. 2010;51:1472-1479.
-
(2010)
J Nucl Med
, vol.51
, pp. 1472-1479
-
-
Watanabe, S.1
Hanaoka, H.2
Liang, J.X.3
Iida, Y.4
Endo, K.5
Ishioka, N.S.6
-
48
-
-
84938923518
-
124I-MIBG: A new promising positronemitting radiopharmaceutical for the evaluation of neuroblastoma
-
Cistaro A, Quartuccio N, Caobelli F, et al. 124I-MIBG: a new promising positronemitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18:102-106.
-
(2015)
Nucl Med Rev Cent East Eur
, vol.18
, pp. 102-106
-
-
Cistaro, A.1
Quartuccio, N.2
Caobelli, F.3
-
50
-
-
0030019363
-
No-carrier-added (4-fluoro-3-[131I] iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine
-
Vaidyanathan G, Affleck DJ, Zalutsky MR. No-carrier-added (4-fluoro-3-[131I] iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. Bioconjug Chem. 1996;7:102-107.
-
(1996)
Bioconjug Chem
, vol.7
, pp. 102-107
-
-
Vaidyanathan, G.1
Affleck, D.J.2
Zalutsky, M.R.3
-
51
-
-
84913533561
-
Case report of PET/CT imaging of a patient with neuroblastoma using 18F-FPBG
-
Suh M, Park HJ, Choi HS, So Y, Lee BC, Lee WW. Case report of PET/CT imaging of a patient with neuroblastoma using 18F-FPBG. Pediatrics. 2014;134: e1731-e1734.
-
(2014)
Pediatrics
, vol.134
, pp. e1731-e1734
-
-
Suh, M.1
Park, H.J.2
Choi, H.S.3
So, Y.4
Lee, B.C.5
Lee, W.W.6
-
52
-
-
85028815302
-
Biodistribution and dosimetry of (18)F-meta fluorobenzyl guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies
-
Jul. 13, [Epub ahead of print]
-
Pandit-Taskar N, Zanzonico PB, Staton KD, et al. Biodistribution and dosimetry of (18)F-meta fluorobenzyl guanidine (MFBG): a first-in-human PET-CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. Jul. 13, 2017 [Epub ahead of print].
-
(2017)
J Nucl Med.
-
-
Pandit-Taskar, N.1
Zanzonico, P.B.2
Staton, K.D.3
-
53
-
-
84921778155
-
11C-mHED for PET/CT: Principles of synthesis, methodology and first clinical applications
-
Bonfiglioli R, Nanni C, Martignani C, et al. 11C-mHED for PET/CT: principles of synthesis, methodology and first clinical applications. Curr Radiopharm. 2014;7:79-83.
-
(2014)
Curr Radiopharm
, vol.7
, pp. 79-83
-
-
Bonfiglioli, R.1
Nanni, C.2
Martignani, C.3
-
54
-
-
34247179545
-
Whole-body PET/CT with 11Cmeta- hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT
-
Franzius C, Hermann K, Weckesser M, et al. Whole-body PET/CT with 11Cmeta- hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47: 1635-1642.
-
(2006)
J Nucl Med
, vol.47
, pp. 1635-1642
-
-
Franzius, C.1
Hermann, K.2
Weckesser, M.3
-
55
-
-
9244257319
-
PET hydroxyephedrine imaging of neuroblastoma
-
Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16-21.
-
(1996)
J Nucl Med
, vol.37
, pp. 16-21
-
-
Shulkin, B.L.1
Wieland, D.M.2
Baro, M.E.3
-
56
-
-
31544456412
-
[11C] metahydroxyephedrine and [18F] fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma
-
Mann GN, Link JM, Pham P, et al. [11C]metahydroxyephedrine and [18F] fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13: 187-197.
-
(2006)
Ann Surg Oncol
, vol.13
, pp. 187-197
-
-
Mann, G.N.1
Link, J.M.2
Pham, P.3
-
57
-
-
0030309723
-
Neurotransmitter transporters: New insights into structure, function and pharmacology
-
Amara SG. Neurotransmitter transporters: new insights into structure, function and pharmacology. Rev Bras Biol. 1996;56(suppl 1):5-19.
-
(1996)
Rev Bras Biol
, vol.56
, pp. 5-19
-
-
Amara, S.G.1
-
58
-
-
0026028074
-
Synthesis of high specific activity 6-[18F]fluorodopamine for positron emission tomography studies of sympathetic nervous tissue
-
Ding YS, Fowler JS, Gatley SJ, Dewey SL, Wolf AP, Schlyer DJ. Synthesis of high specific activity 6-[18F]fluorodopamine for positron emission tomography studies of sympathetic nervous tissue. J Med Chem. 1991;34: 861-863.
-
(1991)
J Med Chem
, vol.34
, pp. 861-863
-
-
Ding, Y.S.1
Fowler, J.S.2
Gatley, S.J.3
Dewey, S.L.4
Wolf, A.P.5
Schlyer, D.J.6
-
59
-
-
0030613015
-
On the accuracy of an [18F]FDOPA compartmental model: Evidence for vesicular storage of [18F]fluorodopamine in vivo
-
Deep P, Gjedde A, Cumming P. On the accuracy of an [18F]FDOPA compartmental model: evidence for vesicular storage of [18F]fluorodopamine in vivo. J Neurosci Methods. 1997;76:157-165.
-
(1997)
J Neurosci Methods
, vol.76
, pp. 157-165
-
-
Deep, P.1
Gjedde, A.2
Cumming, P.3
-
60
-
-
84902238890
-
6-[18F]fluoro-L-DOPA: A well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses
-
Pretze M, Wangler C, Wangler B. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. Biomed Res Int. 2014;2014:674063.
-
(2014)
Biomed Res Int
, vol.2014
, pp. 674063
-
-
Pretze, M.1
Wangler, C.2
Wangler, B.3
-
61
-
-
84920380789
-
In vivo biodistribution of no-carrieradded 6-18F-fluoro-3, 4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18FDOPA, prepared by conventional electrophilic substitution
-
Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrieradded 6-18F-fluoro-3, 4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18FDOPA, prepared by conventional electrophilic substitution. J Nucl Med. 2015; 56:106-112.
-
(2015)
J Nucl Med
, vol.56
, pp. 106-112
-
-
Kuik, W.J.1
Kema, I.P.2
Brouwers, A.H.3
-
62
-
-
53749086628
-
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma
-
Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613-1619.
-
(2008)
J Nucl Med
, vol.49
, pp. 1613-1619
-
-
Ilias, I.1
Chen, C.C.2
Carrasquillo, J.A.3
-
63
-
-
65549141729
-
The clinical value of [18F]fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
-
Kauhanen S, Seppänen M, Ovaska J, et al. The clinical value of [18F]fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009; 16:255-265.
-
(2009)
Endocr Relat Cancer
, vol.16
, pp. 255-265
-
-
Kauhanen, S.1
Seppänen, M.2
Ovaska, J.3
-
64
-
-
77949273307
-
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma
-
Luster M, Karges W, Zeich K, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37: 484-493.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 484-493
-
-
Luster, M.1
Karges, W.2
Zeich, K.3
-
65
-
-
84879258016
-
123I-MIBG, 18F-DOPA and 18FFDG in a patient with MEN2 syndrome and recurrent pheochromocytoma
-
Cuenca-Cuenca JI, Marín-Oyaga VA, Borrego-Dorado I, Navarro-González E, Martos-Martínez JM, Vázquez-Albertino R. 123I-MIBG, 18F-DOPA and 18FFDG in a patient with MEN2 syndrome and recurrent pheochromocytoma. Rev Esp Med Nucl Imagen Mol. 2013;32:263-265.
-
(2013)
Rev Esp Med Nucl Imagen Mol
, vol.32
, pp. 263-265
-
-
Cuenca-Cuenca, J.I.1
Marín-Oyaga, V.A.2
Borrego-Dorado, I.3
Navarro-González, E.4
Martos-Martínez, J.M.5
Vázquez-Albertino, R.6
-
66
-
-
84891556013
-
18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes
-
Marzola MC, Chondrogiannis S, Grassetto G, et al. 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes. Clin Nucl Med. 2014;39:e53-e58.
-
(2014)
Clin Nucl Med
, vol.39
, pp. e53-e58
-
-
Marzola, M.C.1
Chondrogiannis, S.2
Grassetto, G.3
-
67
-
-
84858147946
-
18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR
-
Lopci E, Piccardo A, Nanni C, et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med. 2012;37: e73-e78.
-
(2012)
Clin Nucl Med
, vol.37
, pp. e73-e78
-
-
Lopci, E.1
Piccardo, A.2
Nanni, C.3
-
68
-
-
84899415680
-
18F-DOPA PET/CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma
-
Piccardo A, Lopci E, Foppiani L, Morana G, Conte M. 18F-DOPA PET/CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatr Radiol. 2014;44:355-361.
-
(2014)
Pediatr Radiol
, vol.44
, pp. 355-361
-
-
Piccardo, A.1
Lopci, E.2
Foppiani, L.3
Morana, G.4
Conte, M.5
-
69
-
-
84900789874
-
Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma
-
Piccardo A, Puntoni M, Lopci E, et al. Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014;41:1046-1056.
-
(2014)
Eur J Nucl Med Mol Imaging
, vol.41
, pp. 1046-1056
-
-
Piccardo, A.1
Puntoni, M.2
Lopci, E.3
-
70
-
-
84858776675
-
Comparison of 18F-dopa PET/CT and 123IMIBG scintigraphy in stage 3 and 4 neuroblastoma: A pilot study
-
Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123IMIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57-71.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 57-71
-
-
Piccardo, A.1
Lopci, E.2
Conte, M.3
-
72
-
-
84958608996
-
Arsenic trioxide as radiation sensitizer for 131I-metaiodobenzylguanidine therapy: Results of a phase II study
-
Modak S, Zanzonico P, Carrasquillo JA, et al. Arsenic trioxide as radiation sensitizer for 131I-metaiodobenzylguanidine therapy: results of a phase II study. J Nucl Med. 2016;57:231-237.
-
(2016)
J Nucl Med
, vol.57
, pp. 231-237
-
-
Modak, S.1
Zanzonico, P.2
Carrasquillo, J.A.3
-
73
-
-
84875000890
-
131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma
-
French S, DuBois SG, Horn B, et al. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013;60:879-884.
-
(2013)
Pediatr Blood Cancer
, vol.60
, pp. 879-884
-
-
French, S.1
DuBois, S.G.2
Horn, B.3
-
74
-
-
84941979029
-
Phase i study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma
-
DuBois SG, Groshen S, Park JR, et al. Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. Clin Cancer Res. 2015;21: 2715-2721.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2715-2721
-
-
DuBois, S.G.1
Groshen, S.2
Park, J.R.3
-
75
-
-
84923562128
-
Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
-
DuBois SG, Allen S, Bent M, et al. Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015;112:644-649.
-
(2015)
Br J Cancer
, vol.112
, pp. 644-649
-
-
DuBois, S.G.1
Allen, S.2
Bent, M.3
-
76
-
-
0026512655
-
I-131 MIBG imaging after bone marrow transplantation for neuroblastoma
-
Englaro EE, Gelfand MJ, Harris RE, Smith HS. I-131 MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology. 1992;182:515-520.
-
(1992)
Radiology
, vol.182
, pp. 515-520
-
-
Englaro, E.E.1
Gelfand, M.J.2
Harris, R.E.3
Smith, H.S.4
-
77
-
-
0035099689
-
Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
-
Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer. 2001;84: 460-464.
-
(2001)
Br J Cancer
, vol.84
, pp. 460-464
-
-
Mastrangelo, S.1
Tornesello, A.2
Diociaiuti, L.3
-
78
-
-
33644846781
-
Phase i dose escalation of iodine- 131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study
-
Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine- 131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol. 2006;24:500-506.
-
(2006)
J Clin Oncol
, vol.24
, pp. 500-506
-
-
Matthay, K.K.1
Tan, J.C.2
Villablanca, J.G.3
-
79
-
-
84863460418
-
Dose escalation study of nocarrier- added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium trial
-
Matthay KK, Weiss B, Villablanca JG, et al. Dose escalation study of nocarrier- added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium trial. J Nucl Med. 2012;53:1155-1163.
-
(2012)
J Nucl Med
, vol.53
, pp. 1155-1163
-
-
Matthay, K.K.1
Weiss, B.2
Villablanca, J.G.3
-
80
-
-
34047214104
-
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
-
Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25: 1054-1060.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1054-1060
-
-
Matthay, K.K.1
Yanik, G.2
Messina, J.3
-
81
-
-
0022896880
-
Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine
-
Treuner J, Klingebiel T, Feine U, et al. Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Pediatr Hematol Oncol. 1986;3:205-216.
-
(1986)
Pediatr Hematol Oncol
, vol.3
, pp. 205-216
-
-
Treuner, J.1
Klingebiel, T.2
Feine, U.3
-
82
-
-
0025868778
-
Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial
-
Klingebiel T, Berthold F, Treuner J, et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol. 1991;19:84-88.
-
(1991)
Med Pediatr Oncol
, vol.19
, pp. 84-88
-
-
Klingebiel, T.1
Berthold, F.2
Treuner, J.3
-
83
-
-
0027093713
-
Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation
-
Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992;10:1889-1896.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1889-1896
-
-
Lashford, L.S.1
Lewis, I.J.2
Fielding, S.L.3
-
84
-
-
2942702182
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
-
DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004;22:2452-2460.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2452-2460
-
-
DuBois, S.G.1
Messina, J.2
Maris, J.M.3
-
85
-
-
0031961810
-
Phase i dose escalation of 131Imetaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
-
Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131Imetaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229-236.
-
(1998)
J Clin Oncol
, vol.16
, pp. 229-236
-
-
Matthay, K.K.1
DeSantes, K.2
Hasegawa, B.3
-
86
-
-
0028066597
-
Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine
-
Sisson JC, Shapiro B, Hutchinson RJ, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med. 1994;21:46-52.
-
(1994)
Eur J Nucl Med
, vol.21
, pp. 46-52
-
-
Sisson, J.C.1
Shapiro, B.2
Hutchinson, R.J.3
-
87
-
-
84894043940
-
A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
-
Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50:801-815.
-
(2014)
Eur J Cancer
, vol.50
, pp. 801-815
-
-
Wilson, J.S.1
Gains, J.E.2
Moroz, V.3
Wheatley, K.4
Gaze, M.N.5
-
88
-
-
84943661827
-
Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)
-
Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG). Eur J Cancer. 2015;51:2465-2472.
-
(2015)
Eur J Cancer
, vol.51
, pp. 2465-2472
-
-
Zhou, M.J.1
Doral, M.Y.2
DuBois, S.G.3
Villablanca, J.G.4
Yanik, G.A.5
Matthay, K.K.6
-
89
-
-
84885423323
-
Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: A retrospective analysis
-
Bleeker G, Schoot RA, Caron HN, et al. Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2013;40: 1711-1717.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 1711-1717
-
-
Bleeker, G.1
Schoot, R.A.2
Caron, H.N.3
-
90
-
-
79954492593
-
Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen
-
Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer. 2011;56:1032-1040.
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 1032-1040
-
-
Mastrangelo, S.1
Rufini, V.2
Ruggiero, A.3
Di Giannatale, A.4
Riccardi, R.5
-
91
-
-
40249095844
-
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age
-
de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008;44: 551-556.
-
(2008)
Eur J Cancer
, vol.44
, pp. 551-556
-
-
De Kraker, J.1
Hoefnagel, K.A.2
Verschuur, A.C.3
Van Eck, B.4
Van Santen, H.M.5
Caron, H.N.6
-
92
-
-
85015399036
-
Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients
-
Kraal KC, Bleeker GM, van Eck-Smit BL, et al. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer. 2017;76:188-196.
-
(2017)
Eur J Cancer
, vol.76
, pp. 188-196
-
-
Kraal, K.C.1
Bleeker, G.M.2
Van Eck-Smit, B.L.3
-
93
-
-
84922819635
-
Nothing but NET: A review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy
-
Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer. 2015;62:5-11.
-
(2015)
Pediatr Blood Cancer
, vol.62
, pp. 5-11
-
-
Streby, K.A.1
Shah, N.2
Ranalli, M.A.3
Kunkler, A.4
Cripe, T.P.5
-
94
-
-
79960921406
-
Safety and efficacy of tandem 131Imetaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma
-
Johnson K, McGlynn B, Saggio J, et al. Safety and efficacy of tandem 131Imetaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2011;57:1124-1129.
-
(2011)
Pediatr Blood Cancer
, vol.57
, pp. 1124-1129
-
-
Johnson, K.1
McGlynn, B.2
Saggio, J.3
-
95
-
-
0026088777
-
Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine
-
Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991;67:922-928.
-
(1991)
Cancer
, vol.67
, pp. 922-928
-
-
Garaventa, A.1
Guerra, P.2
Arrighini, A.3
-
96
-
-
33748565275
-
Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for the German Neuroblastoma Trial NB2004
-
Schmidt M, Simon T, Hero B, et al. Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. 2006;45:145-151.
-
(2006)
Nuklearmedizin
, vol.45
, pp. 145-151
-
-
Schmidt, M.1
Simon, T.2
Hero, B.3
-
97
-
-
0026357902
-
[131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma
-
Hoefnagel CA, Voûte PA, De Kraker J, Valdés Olmos RA. [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl BiolMed. 1991;35: 202-206.
-
(1991)
J Nucl BiolMed
, vol.35
, pp. 202-206
-
-
Hoefnagel, C.A.1
Voûte, P.A.2
De Kraker, J.3
Valdés Olmos, R.A.4
-
98
-
-
0026405073
-
Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: A phase II study in 26 patients
-
Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. J Nucl Biol Med. 1991;35:220-223.
-
(1991)
J Nucl Biol Med
, vol.35
, pp. 220-223
-
-
Lumbroso, J.1
Hartmann, O.2
Schlumberger, M.3
-
99
-
-
0021357316
-
Platelet uptake of the pheochromocytomascanning agent meta-iodobenzylguanadine-I-131
-
Feldman JM, Frankel N, Coleman RE. Platelet uptake of the pheochromocytomascanning agent meta-iodobenzylguanadine-I-131. Metabolism. 1984;33:397-399.
-
(1984)
Metabolism
, vol.33
, pp. 397-399
-
-
Feldman, J.M.1
Frankel, N.2
Coleman, R.E.3
-
100
-
-
42349094437
-
Transient sialoadenitis: A complication of 131I-metaiodobenzylguanidine therapy
-
Modak S, Pandit-Taskar N, Kushner BH, et al. Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer. 2008;50: 1271-1273.
-
(2008)
Pediatr Blood Cancer
, vol.50
, pp. 1271-1273
-
-
Modak, S.1
Pandit-Taskar, N.2
Kushner, B.H.3
-
101
-
-
78650143642
-
Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma
-
Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56:191-201.
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 191-201
-
-
Quach, A.1
Ji, L.2
Mishra, V.3
-
102
-
-
84880361970
-
Acute changes in blood pressure in patients with neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG)
-
Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG. Acute changes in blood pressure in patients with neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2013;60:1424-1430.
-
(2013)
Pediatr Blood Cancer
, vol.60
, pp. 1424-1430
-
-
Wong, T.1
Matthay, K.K.2
Boscardin, W.J.3
Hawkins, R.A.4
Brakeman, P.R.5
DuBois, S.G.6
-
103
-
-
84983483003
-
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131Imetaiodobenzylguanidine
-
Huibregtse KE, Vo KT, DuBois SG, et al. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131Imetaiodobenzylguanidine. Eur J Cancer. 2016;66:144-152.
-
(2016)
Eur J Cancer
, vol.66
, pp. 144-152
-
-
Huibregtse, K.E.1
Vo, K.T.2
DuBois, S.G.3
-
104
-
-
0345074094
-
Second malignancies in children with neuroblastoma after combined treatment with I-131-metaiodobenzylguanidine
-
Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with I-131-metaiodobenzylguanidine. Cancer. 2003;97:1332-1338.
-
(2003)
Cancer
, vol.97
, pp. 1332-1338
-
-
Garaventa, A.1
Gambini, C.2
Villavecchia, G.3
-
105
-
-
84894556457
-
Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity
-
Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108-119.
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 108-119
-
-
Dahia, P.L.1
-
106
-
-
0031443099
-
The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients
-
Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-658.
-
(1997)
J Endocrinol Invest
, vol.20
, pp. 648-658
-
-
Loh, K.C.1
Fitzgerald, P.A.2
Matthay, K.K.3
Yeo, P.P.4
Price, D.C.5
-
107
-
-
77952499376
-
131I-MIBG treatment of pheochromocytoma: Low versus intermediate activity regimens of therapy
-
Castellani MR, Seghezzi S, Chiesa C, et al. 131I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010;54:100-113.
-
(2010)
Q J Nucl Med Mol Imaging
, vol.54
, pp. 100-113
-
-
Castellani, M.R.1
Seghezzi, S.2
Chiesa, C.3
-
108
-
-
70249133742
-
Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma
-
Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-4168.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4162-4168
-
-
Gonias, S.1
Goldsby, R.2
Matthay, K.K.3
-
109
-
-
84919789475
-
Effects and safety of 131Imetaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
-
Yoshinaga K, Oriuchi N, Wakabayashi H, et al. Effects and safety of 131Imetaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014;61: 1171-1180.
-
(2014)
Endocr J
, vol.61
, pp. 1171-1180
-
-
Yoshinaga, K.1
Oriuchi, N.2
Wakabayashi, H.3
-
110
-
-
84962875281
-
I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma
-
Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma. Semin Nucl Med. 2016;46:203-214.
-
(2016)
Semin Nucl Med
, vol.46
, pp. 203-214
-
-
Carrasquillo, J.A.1
Pandit-Taskar, N.2
Chen, C.C.3
-
111
-
-
10744221975
-
Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma
-
Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956-962.
-
(2003)
Surgery
, vol.134
, pp. 956-962
-
-
Safford, S.D.1
Coleman, R.E.2
Gockerman, J.P.3
-
113
-
-
84954198671
-
Management of metastatic phaeochromocytoma and paraganglioma: Use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre
-
Rutherford MA, Rankin AJ, Yates TM, et al. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM. 2015;108:361-368.
-
(2015)
QJM
, vol.108
, pp. 361-368
-
-
Rutherford, M.A.1
Rankin, A.J.2
Yates, T.M.3
-
114
-
-
84895924028
-
131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: Systematic review and meta-analysis
-
van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487-501.
-
(2014)
Clin Endocrinol (Oxf)
, vol.80
, pp. 487-501
-
-
Van Hulsteijn, L.T.1
Niemeijer, N.D.2
Dekkers, O.M.3
Corssmit, E.P.4
-
115
-
-
84890311276
-
Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
-
Wakabayashi H, Taki J, Inaki A, et al. Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med. 2013;27:839-846.
-
(2013)
Ann Nucl Med
, vol.27
, pp. 839-846
-
-
Wakabayashi, H.1
Taki, J.2
Inaki, A.3
-
116
-
-
76749164800
-
Low-dose iodine- 131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: Single center experience
-
Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine- 131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol. 2010;33: 79-82.
-
(2010)
Am J Clin Oncol
, vol.33
, pp. 79-82
-
-
Shilkrut, M.1
Bar-Deroma, R.2
Bar-Sela, G.3
Berniger, A.4
Kuten, A.5
-
117
-
-
0022623256
-
Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine
-
Hoefnagel CA, Den Hartog Jager FC, Van Gennip AH, Marcuse HR, Taal BG. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med. 1986;11:150-152.
-
(1986)
Clin Nucl Med
, vol.11
, pp. 150-152
-
-
Hoefnagel, C.A.1
Den Hartog Jager, F.C.2
Van Gennip, A.H.3
Marcuse, H.R.4
Taal, B.G.5
-
118
-
-
0034933953
-
I-131-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome
-
Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ. I-131-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol. 2001;27:404-408.
-
(2001)
Eur J Surg Oncol
, vol.27
, pp. 404-408
-
-
Pathirana, A.A.1
Vinjamuri, S.2
Byrne, C.3
Ghaneh, P.4
Vora, J.5
Poston, G.J.6
-
119
-
-
0035724711
-
Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with I-131-meta-iodobenzylguanidine (I-131-mIBG)
-
Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with I-131-meta-iodobenzylguanidine (I-131-mIBG). Clin Endocrinol (Oxf). 2001;55:47-60.
-
(2001)
Clin Endocrinol (Oxf)
, vol.55
, pp. 47-60
-
-
Mukherjee, J.J.1
Kaltsas, G.A.2
Islam, N.3
-
120
-
-
7044237270
-
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid: Results in 98 patients
-
Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid: results in 98 patients. Cancer. 2004; 101:1987-1993.
-
(2004)
Cancer
, vol.101
, pp. 1987-1993
-
-
Safford, S.D.1
Coleman, R.E.2
Gockerman, J.P.3
-
121
-
-
0028887958
-
No-carrier-added meta-[123I]iodobenzylguanidine: Synthesis and preliminary evaluation
-
Vaidyanathan G, Zalutsky MR. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol. 1995;22:61-64.
-
(1995)
Nucl Med Biol
, vol.22
, pp. 61-64
-
-
Vaidyanathan, G.1
Zalutsky, M.R.2
-
122
-
-
77954910396
-
Comparison of high-specific-activity Ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution
-
Barrett JA, Joyal JL, Hillier SM, et al. Comparison of high-specific-activity Ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25:299-308.
-
(2010)
Cancer Biother Radiopharm
, vol.25
, pp. 299-308
-
-
Barrett, J.A.1
Joyal, J.L.2
Hillier, S.M.3
-
123
-
-
84901353141
-
Phase-1 clinical trial results of highspecific- activity carrier-free 123I-iobenguane
-
Chin BB, Kronauge JF, Femia FJ, et al. Phase-1 clinical trial results of highspecific- activity carrier-free 123I-iobenguane. J Nucl Med. 2014;55:765-771.
-
(2014)
J Nucl Med
, vol.55
, pp. 765-771
-
-
Chin, B.B.1
Kronauge, J.F.2
Femia, F.J.3
-
124
-
-
0034184715
-
No-carrier-added I-123-MIBG: An initial clinical study in patients with phaeochromocytoma
-
Owens J, Bolster AA, Prosser JE, et al. No-carrier-added I-123-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun. 2000;21:437-440.
-
(2000)
Nucl Med Commun
, vol.21
, pp. 437-440
-
-
Owens, J.1
Bolster, A.A.2
Prosser, J.E.3
-
125
-
-
0141958084
-
Targeted radiotherapy with submyeloablative doses of I-131-MIBG is effective for disease palliation in highly refractory neuroblastoma
-
Kang TI, Brophy P, Hickeson M, et al. Targeted radiotherapy with submyeloablative doses of I-131-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol. 2003;25:769-773.
-
(2003)
J Pediatr Hematol Oncol
, vol.25
, pp. 769-773
-
-
Kang, T.I.1
Brophy, P.2
Hickeson, M.3
-
126
-
-
18844423539
-
Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma
-
Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20:195-199.
-
(2005)
Cancer Biother Radiopharm
, vol.20
, pp. 195-199
-
-
Gaze, M.N.1
Chang, Y.C.2
Flux, G.D.3
Mairs, R.J.4
Saran, F.H.5
Meller, S.T.6
-
127
-
-
0026482679
-
The treatment of resistant neuroblastoma with 131I-mIBG: Alternative methods of dose prescription
-
Fielding SL, Flower MA, Ackery DM, Kemshead J, Lashford LS, Lewis IJ. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription. Radiother Oncol. 1992;25:73-76.
-
(1992)
Radiother Oncol
, vol.25
, pp. 73-76
-
-
Fielding, S.L.1
Flower, M.A.2
Ackery, D.M.3
Kemshead, J.4
Lashford, L.S.5
Lewis, I.J.6
-
128
-
-
0025797431
-
Dosimetry of I-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: Results of a UK study
-
Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of I-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991;18:308-316.
-
(1991)
Eur J Nucl Med
, vol.18
, pp. 308-316
-
-
Fielding, S.L.1
Flower, M.A.2
Ackery, D.3
Kemshead, J.T.4
Lashford, L.S.5
Lewis, I.6
-
129
-
-
34247869771
-
Dosimetry for fractionated I-131-mIBG therapies in patients with primary resistant high-risk neuroblastoma: Preliminary results
-
Buckley SE, Saran FH, Gaze MN, et al. Dosimetry for fractionated I-131-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22:105-112.
-
(2007)
Cancer Biother Radiopharm
, vol.22
, pp. 105-112
-
-
Buckley, S.E.1
Saran, F.H.2
Gaze, M.N.3
-
130
-
-
0035205508
-
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG
-
Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nucl Med. 2001;42:1713-1721.
-
(2001)
J Nucl Med
, vol.42
, pp. 1713-1721
-
-
Matthay, K.K.1
Panina, C.2
Huberty, J.3
-
131
-
-
84956571721
-
Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with 131Imetaiodobenzylguanidine (MIBG)
-
Trieu M, DuBois SG, Pon E, et al. Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with 131Imetaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016;63:436-442.
-
(2016)
Pediatr Blood Cancer
, vol.63
, pp. 436-442
-
-
Trieu, M.1
DuBois, S.G.2
Pon, E.3
-
132
-
-
0026378640
-
Radiopharmaceutical therapy of malignant pheochromocytoma with I-131 metaiodobenzylguanidine: Results from ten years of experience
-
Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with I-131 metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med. 1991;35:269-276.
-
(1991)
J Nucl Biol Med
, vol.35
, pp. 269-276
-
-
Shapiro, B.1
Sisson, J.C.2
Wieland, D.M.3
-
133
-
-
69249133840
-
Radiation dosimetry, pharmacokinetics, and safety of UltratraceTM Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid
-
Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, Babich JW. Radiation dosimetry, pharmacokinetics, and safety of UltratraceTM Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm. 2009;24:469-475.
-
(2009)
Cancer Biother Radiopharm
, vol.24
, pp. 469-475
-
-
Coleman, R.E.1
Stubbs, J.B.2
Barrett, J.A.3
De La Guardia, M.4
Lafrance, N.5
Babich, J.W.6
-
134
-
-
85028845596
-
Assessment of organ dosimetry for planning repeat treatments of high-dose 131I-MIBG therapy: 123I-MIBG versus posttherapy 131I-MIBG imaging
-
[Epub ahead of print]
-
Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S. Assessment of organ dosimetry for planning repeat treatments of high-dose 131I-MIBG therapy: 123I-MIBG versus posttherapy 131I-MIBG imaging. Clin Nucl Med. Jul. 29, 2017 [Epub ahead of print].
-
(2017)
Clin Nucl Med. Jul.
, vol.29
-
-
Pandit-Taskar, N.1
Zanzonico, P.2
Hilden, P.3
Ostrovnaya, I.4
Carrasquillo, J.A.5
Modak, S.6
-
135
-
-
77956318239
-
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET
-
Lee CL, Wahnishe H, Sayre GA, et al. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010;37:4861-4867.
-
(2010)
Med Phys
, vol.37
, pp. 4861-4867
-
-
Lee, C.L.1
Wahnishe, H.2
Sayre, G.A.3
-
136
-
-
84870403525
-
Tumor dosimetry using [124I]miodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model
-
Seo Y, Gustafson WC, Dannoon SF, et al. Tumor dosimetry using [124I]miodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012;14: 735-742.
-
(2012)
Mol Imaging Biol
, vol.14
, pp. 735-742
-
-
Seo, Y.1
Gustafson, W.C.2
Dannoon, S.F.3
-
137
-
-
0026611908
-
Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography
-
Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol. 1992;65:787-791.
-
(1992)
Br J Radiol
, vol.65
, pp. 787-791
-
-
Ott, R.J.1
Tait, D.2
Flower, M.A.3
Babich, J.W.4
Lambrecht, R.M.5
-
138
-
-
0026951114
-
1-(m-[211At]astatobenzyl)guanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation
-
Vaidyanathan G, Zalutsky MR. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem. 1992;3:499-503.
-
(1992)
Bioconjug Chem
, vol.3
, pp. 499-503
-
-
Vaidyanathan, G.1
Zalutsky, M.R.2
-
139
-
-
34047131771
-
A kit method for the high level synthesis of [211At]MABG
-
Vaidyanathan G, Affleck DJ, Alston KL, et al. A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem. 2007;15:3430-3436.
-
(2007)
Bioorg Med Chem
, vol.15
, pp. 3430-3436
-
-
Vaidyanathan, G.1
Affleck, D.J.2
Alston, K.L.3
-
140
-
-
0028177363
-
Meta-[211At]astatobenzylguanidine: Further evaluation of a potential therapeutic agent
-
Vaidyanathan G, Strickland DK, Zalutsky MR. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer. 1994;57:908-913.
-
(1994)
Int J Cancer
, vol.57
, pp. 908-913
-
-
Vaidyanathan, G.1
Strickland, D.K.2
Zalutsky, M.R.3
-
141
-
-
0030203688
-
Evaluation of meta- [211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model
-
Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR. Evaluation of meta- [211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol. 1996;23:851-856.
-
(1996)
Nucl Med Biol
, vol.23
, pp. 851-856
-
-
Vaidyanathan, G.1
Friedman, H.S.2
Keir, S.T.3
Zalutsky, M.R.4
-
143
-
-
79954620898
-
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
-
More SS, Itsara M, Yang X, et al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011;17:2339-2349.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2339-2349
-
-
More, S.S.1
Itsara, M.2
Yang, X.3
-
144
-
-
49049090026
-
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination
-
McCluskey AG, Boyd M, Pimlott SL, Babich JW, Gaze MN, Mairs RJ. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination. Br J Radiol. 2008;81(special issue):S28-S35.
-
(2008)
Br J Radiol
, vol.81
, pp. S28-S35
-
-
McCluskey, A.G.1
Boyd, M.2
Pimlott, S.L.3
Babich, J.W.4
Gaze, M.N.5
Mairs, R.J.6
-
145
-
-
77953712305
-
Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis
-
Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy. 2010;6:353-365.
-
(2010)
Autophagy
, vol.6
, pp. 353-365
-
-
Chiu, H.W.1
Lin, J.H.2
Chen, Y.A.3
Ho, S.Y.4
Wang, Y.J.5
-
146
-
-
0031050382
-
The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro
-
Armour A, Cunningham SH, Gaze MN, Wheldon TE, Mairs RJ. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer. 1997;75:470-476.
-
(1997)
Br J Cancer
, vol.75
, pp. 470-476
-
-
Armour, A.1
Cunningham, S.H.2
Gaze, M.N.3
Wheldon, T.E.4
Mairs, R.J.5
-
147
-
-
84863448705
-
Inhibition of poly(ADP-ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter
-
McCluskey AG, Mairs RJ, Tesson M, et al. Inhibition of poly(ADP-ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. J Nucl Med. 2012;53:1146-1154.
-
(2012)
J Nucl Med
, vol.53
, pp. 1146-1154
-
-
McCluskey, A.G.1
Mairs, R.J.2
Tesson, M.3
-
148
-
-
84924266449
-
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) phase II study
-
Yanik GA, Villablanca JG, Maris JM, et al. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015;21:673-681.
-
(2015)
Biol Blood Marrow Transplant
, vol.21
, pp. 673-681
-
-
Yanik, G.A.1
Villablanca, J.G.2
Maris, J.M.3
-
149
-
-
0023789889
-
Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine
-
Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267-273.
-
(1988)
Ann Intern Med
, vol.109
, pp. 267-273
-
-
Averbuch, S.D.1
Steakley, C.S.2
Young, R.C.3
-
150
-
-
0033501955
-
Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy
-
Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S, Spaulding S. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:364-370.
-
(1999)
Am J Clin Oncol
, vol.22
, pp. 364-370
-
-
Sisson, J.C.1
Shapiro, B.2
Shulkin, B.L.3
Urba, S.4
Zempel, S.5
Spaulding, S.6
-
151
-
-
84944342532
-
Combined treatment with 131IMIBG and sunitinib induces remission in a patient with metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation
-
Makis W, McCann K, McEwan AJ, Sawyer MB. Combined treatment with 131IMIBG and sunitinib induces remission in a patient with metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation. Clin Nucl Med. 2016;41:204-206.
-
(2016)
Clin Nucl Med
, vol.41
, pp. 204-206
-
-
Makis, W.1
McCann, K.2
McEwan, A.J.3
Sawyer, M.B.4
-
152
-
-
33745114778
-
Potential increased tumordose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model
-
Madsen MT, Bushnell DL, Juweid ME, et al. Potential increased tumordose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006;47:660-667.
-
(2006)
J Nucl Med
, vol.47
, pp. 660-667
-
-
Madsen, M.T.1
Bushnell, D.L.2
Juweid, M.E.3
-
153
-
-
77951631621
-
Intraarterial 131IMIBG therapy of neuroendocrine tumors with liver metastases
-
Popp M, Strumpf A, Zöphel K, Stroszczynski C, Kotzerke J. Intraarterial 131IMIBG therapy of neuroendocrine tumors with liver metastases. Nuklearmedizin. 2010;49:N2-N3.
-
(2010)
Nuklearmedizin
, vol.49
, pp. N2-N3
-
-
Popp, M.1
Strumpf, A.2
Zöphel, K.3
Stroszczynski, C.4
Kotzerke, J.5
-
154
-
-
33644876364
-
Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of I-131-MIBG
-
Brogsitter C, Pinkert J, Bredow J, Kittner T, Kotzerke J. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of I-131-MIBG. J Nucl Med. 2005;46:2112-2116.
-
(2005)
J Nucl Med
, vol.46
, pp. 2112-2116
-
-
Brogsitter, C.1
Pinkert, J.2
Bredow, J.3
Kittner, T.4
Kotzerke, J.5
-
155
-
-
0038162338
-
Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma
-
Altmann A, Kissel M, Zitzmann S, et al. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med. 2003;44:973-980.
-
(2003)
J Nucl Med
, vol.44
, pp. 973-980
-
-
Altmann, A.1
Kissel, M.2
Zitzmann, S.3
-
156
-
-
3543108178
-
Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells
-
Anton M, Wagner B, Haubner R, et al. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004;6:119-126.
-
(2004)
J Gene Med
, vol.6
, pp. 119-126
-
-
Anton, M.1
Wagner, B.2
Haubner, R.3
-
157
-
-
33644875886
-
The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/ reporter probe for PET of gene therapy
-
Buursma AR, Beerens AM, de Vries EF, et al. The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/ reporter probe for PET of gene therapy. J Nucl Med. 2005;46:2068-2075.
-
(2005)
J Nucl Med
, vol.46
, pp. 2068-2075
-
-
Buursma, A.R.1
Beerens, A.M.2
De Vries, E.F.3
-
158
-
-
34250681881
-
Imaging hNET reporter gene expression with 124I-MIBG
-
Moroz MA, Serganova I, Zanzonico P, et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007;48:827-836.
-
(2007)
J Nucl Med
, vol.48
, pp. 827-836
-
-
Moroz, M.A.1
Serganova, I.2
Zanzonico, P.3
-
159
-
-
66649123890
-
Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene
-
Brader P, Kelly KJ, Chen N, et al. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. Clin Cancer Res. 2009;15:3791-3801.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3791-3801
-
-
Brader, P.1
Kelly, K.J.2
Chen, N.3
-
160
-
-
84936797187
-
Comparative analysis of T cell imaging with human nuclear reporter genes
-
Moroz MA, Zhang H, Lee J, et al. Comparative analysis of T cell imaging with human nuclear reporter genes. J Nucl Med. 2015;56:1055-1060.
-
(2015)
J Nucl Med
, vol.56
, pp. 1055-1060
-
-
Moroz, M.A.1
Zhang, H.2
Lee, J.3
|